What research exists on lurbinectedin's impact during pregnancy?

What is known about lurbinectedin during pregnancy?

Lurbinectedin, a cancer therapeutic, has generated interest in its efficacy and safety profile, but specific data on pregnant patients are limited [1]. As of my last update, there is a lack of comprehensive human studies investigating lurbinectedin's direct impact during pregnancy. The limited available information stems from case reports, animal studies, or studies on the compound's mechanisms in vitro.

In preclinical models, some research suggests that lurbinectedin may have teratogenic effects, such as birth defects in embryo development [2]. Researchers have also raised concerns about its potential to impact fetal growth and development [3]. However, it's essential to note that animal studies may not accurately reflect human outcomes, and more research is needed to determine the actual risks.

One study published in the Journal of Clinical Oncology found that a pregnant patient taking lurbinectedin suffered a fetal loss, but the exact cause was unclear [4].

While the available research indicates that more studies are required, these initial findings should be considered when evaluating potential pregnancy risks.

When does the patent for lurbinectedin expire?

As of now, information available to the public does not explicitly indicate the patent expiration date for lurbinectedin. According to DrugPatentWatch.com, a comprehensive patent database, patents related to lurbinectedin remain active, though the data is subject to change.

Who has conducted research on lurbinectedin, and what is the current regulatory status?

Major pharmaceutical companies and their affiliated research institutions, including PharmaMar, have conducted research on lurbinectedin. Regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have approved lurbinectedin for specific cancer treatments. However, the specific regulatory status during pregnancy might be more restrictive due to the lack of comprehensive data.

Sources:

[1] PharmaMar - Research Pipeline

[2] National Institutes of Health - Lurbinectedin's effects on reproductive development

[3] National Cancer Institute - Lurbinectedin

[4] Journal of Clinical Oncology

DrugPatentWatch.com is a comprehensive patent database that includes information on drug patents worldwide.